Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

Prior treatment

• Participants currently participating in any interventional clinical trials (regardless of the study drug, excluding observational studies).
• Participants who have undergone lung transplantation.

Other illness

• Discontinuation group only 1) Participants who discontinued AF therapy solely for reasons other than AE (e.g., financial reasons, disease progression).

Other

• Participants meeting any of the following criteria will be excluded from the study:
• <!-- -->

• Participants must meet all the following criteria to be eligible for inclusion in this study:
• Pulmonary fibrosis (PF) participants in Japan. Note: This includes those clinically recognized as having idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF).
• Participants who are ≥18 years of age at the time of providing informed consent via the web-based system.
• Participants receiving outpatient care for pulmonary fibrosis (PF) who have been introduced to this study by a referring physician.
• Participants who have a history of taking, or are currently taking, pirfenidone, nintedanib, or nerandomilast.
• Participants who have experienced at least one antifibrotic (AF) therapy-related adverse event (AE).
  • Discontinuation group only
  • 1\) Participants who have not received AF therapy for at least 1 month prior to enrollment.
  • 2\) Participants whose AF therapy was discontinued within 6 months prior to enrollment.
  • 3\) Participants whose reason for discontinuing AF therapy includes at least one AF therapy-related AE.
• Continuation group only
  • Participants who feel or have felt burdened by the experienced AE.
  • Participants who have continued AF therapy for a specific period (≥6 months) at the time of enrollment.